Teduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage.
AffiliationPaterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester, UK.
MetadataShow full item record
AbstractGlucagon-like peptide-2 and its dipeptidyl peptidase (DP-IV) resistant analogue teduglutide are trophic for the gastrointestinal epithelium. Exposure increases villus height and crypt size and results in increased overall intestinal weight. As these effects may be mediated through stimulation of the stem cell compartment, they may promote intestinal healing and act as potential anti-mucositis agents in patients undergoing cancer chemotherapy. A study was initiated to investigate the protective effects of teduglutide on the murine small intestinal epithelium following gamma-irradiation using the crypt microcolony assay as a measure of stem cell survival and functional competence. Teduglutide demonstrated intestinotrophic effects in both CD1 and BDF1 mouse strains. In BDF1 mice, subcutaneous injection of GLP-2 or teduglutide (0.2 mg/kg/day, b.i.d.) for 14 days increased intestinal weight by 28% and resulted in comparable increases in crypt size, villus height and area. Teduglutide given daily for 6 or 14 days prior to whole body, gamma-irradiation significantly increased crypt stem cell survival when compared with vehicle-treated controls. The mean levels of protection over a range of doses provided protection factors from 1.3 to 1.5. A protective effect was only observed when teduglutide was given before irradiation. These results suggest that teduglutide has the ability to modulate clonogenic stem cell survival in the small intestine and this may have a useful clinical application in the prevention of cancer therapy-induced mucositis.
CitationTeduglutide ([Gly2]GLP-2) protects small intestinal stem cells from radiation damage. 2004, 37 (6):385-400 Cell Prolif.
- Pretreatment with transforming growth factor beta-3 protects small intestinal stem cells against radiation damage in vivo.
- Authors: Potten CS, Booth D, Haley JD
- Issue date: 1997
- Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients.
- Authors: Jeppesen PB, Sanguinetti EL, Buchman A, Howard L, Scolapio JS, Ziegler TR, Gregory J, Tappenden KA, Holst J, Mortensen PB
- Issue date: 2005 Sep
- Transforming growth factor-B3 protects murine small intestinal crypt stem cells and animal survival after irradiation, possibly by reducing stem-cell cycling.
- Authors: Booth D, Haley JD, Bruskin AM, Potten CS
- Issue date: 2000 Apr 1
- A DPP-IV-resistant glucagon-like peptide-2 dimer with enhanced activity against radiation-induced intestinal injury.
- Authors: Gu J, Liu S, Mu N, Huang T, Zhang W, Zhao H, Shu Z, Zhang C, Hao Q, Li W, Xue X, Zhang W, Zhang Y
- Issue date: 2017 Aug 28
- Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome.
- Authors: Thymann T, Stoll B, Mecklenburg L, Burrin DG, Vegge A, Qvist N, Eriksen T, Jeppesen PB, Sangild PT
- Issue date: 2014 Jun